5-alpha reductase inhibitors and erectile dysfunction: The connection

Journal of Sexual Medicine

Volumn 5, Issue 12, 2008, Pages 2917-2924

  Erdemir, Fikret ^a   Harbin, Andrew ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dutasteride; Erectile Dysfunction; Finasteride; Prostate

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROSTANOLONE; AVODAR; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; NITRIC OXIDE SYNTHASE; PLACEBO; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ALOPECIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION DISORDER; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; LIBIDO; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MALE SEXUAL DYSFUNCTION; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PUBLICATION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; TREATMENT DURATION;

EID: 57449107265     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01001.x     Document Type: Article

References (56)

1. NIH Consensus Development Panel on Impotence. Impotence. NIH Consensus conference. JAMA 1993; 270: 83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994; 151: 54-61.
3. Rosen R, Altwein J, Boyle P. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49.
4. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2,869 men using a validated questionnaire. Eur Urol 2005; 47: 80-6.
5. Rosen RC, Wing R, Schneider S, Gendrano N 3rd. Epidemiology of erectile dysfunction: The role of medical comorbidities and lifestyle factors. Urol Clin North Am 2005; 32: 403-17.
6. Napalkov P, Maisonneuve P, Boyle P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995; 46: 41-6.
7. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB. Prospective European doxazosin and combination therapy study investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-26.
8. Hunter HJ. Observations on certain parts of the animal oeconomy. Philos Trans R Soc Lond 1786; 4: 31-6.
9. Uygur MC, Arik AI, Altuǧ U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: A prospective clinical study. Steroids 1998; 63: 208-13.
10. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97: 34-8.
11. Kaplan SA. 5alpha-reductase inhibitors: What role should they play? Urology 2001; 58: 65-70.
12. Roehrborn CG. Acute urinary retention: Risks and management. Rev Urol 2005; 7: 31-41.
13. Schröder FH. Medical treatment of benign prostatic hyperplasia: The effect of surgical or medical castration. Prog Clin Biol Res 1994; 386: 191-6.
14. Kamat NN. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40g. BJU Int 2006; 98: 918.
15. Gratzke C, Schlenker B, Seitz M, Karl A, Hermanek P, Lack N, Stief CG, Reich O. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: Results of a prospective multicenter study. J Urol 2007; 177: 1419-22.
16. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
17. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-35.
18. Lynch TH, PREDICT study. Doxazosin and finasteride alone or in combination: The PREDICT study. BJU Int 2003; 91: 591-2.
19. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM Jr. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25mL or greater. J Urol 2006; 175: 217-20.
20. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-8.
21. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C; ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of long-term treatment with 5-alpha-reductase inhibitor of dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-95.
22. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
23. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327: 1185-91.
24. Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J, PROSCAR Long-Term Efficacy, Safety Study Group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001; 57: 1073-7.
25. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J, Finasteride Study Group. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61: 791-6.
26. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J, PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61: 579-84.
27. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14,772 patients. BJU Int 1996; 78: 379-84.
28. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can Med Assoc J 1996; 155: 1251-9.
29. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-92.
30. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 2005; 48: 269-76.
31. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R. Finasteride 5mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007; 4: 1708-12.
32. UA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-47.
33. Sadeghi-Nejad H, Sherman N, Lue J. Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction. Int J Clin Pract 2003; 57: 484-7.
34. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community based study. CUSP Investigators. Community based study of Proscar. Clin Ther 1995; 17: 956-69.
35. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533-9.
36. Kaufman KD, Olsen EA, Whiting D. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998; 39: 578-89.
37. The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12: 38-49.
38. Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol 2001; 15: 418-21.
39. Tosti A, Pazzaglia M, Soli M, Rossi A, Rebora A, Atzori L, Barbareschi M, Benci M, Voudouris S, Vena GA. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol 2004; 140: 857-8.
40. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F. CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21.
41. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
42. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61: 791-6.
43. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63: 709-15.
44. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials. BMC Urol 2002; 12: 14.
45. Thompson IM, Goodman PJ, Tangen CM. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-4.
46. Hamdy FC. The prostate cancer prevention trial and its messages. Eur Urol 2007; 51: 6-8.
47. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1025-35.
48. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U. Cavernous and systemic testosterone plasma levels during different penile conditions in healthy males and patients with erectile dysfunction. Urology 2001; 58: 435-40.
49. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. Sex Med 2007; 4: 497-501.
50. Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999; 83: 327-33.
51. Seyam RM, Huynh HT, Be'gin LR, Rittmaster RS, Macramalla AN, Abdelbaky TM, Dion SB, Brock GB. 5a-reductase inhibition induces a biphasic regulatory response in transcription of neuronal and endothelial nitric oxide synthase: New insights into the role of androgenic control of erection. J Urol 1997; 157: 1389.
52. Seo SI, Kim SW, Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl 1999; 1: 169-74.
53. Cunningham GR, Hirtshkowitz M. Inhibition of steroid 5a-reductase with finasteride: Sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 1995; 80: 1934-40.
54. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnel JD, Russel DW. Tissue distribution and ontogeny of steroid 5a-reductase isozyme expression. J Clin Invest 1993; 92: 903-10.
55. McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357: 2472-81.
56. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51: 677-86.